Navigation Links
Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
Date:4/23/2010

CALGARY, April 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has completed Phase I patient enrollment in its Phase I/II clinical trial to investigate the use of REOLYSIN(R) for patients with recurrent malignant gliomas (REO 007). The principal investigator is Dr. James Markert, Division Director of Neurosurgery, and Professor, Neurosurgery and Physiology, the University of Alabama at Birmingham.

The Phase I portion of the trial treated 15 patients in five cohorts with doses escalating from 1x10(8) TCID(50) to 1x10(10) TCID(50). The treatment was shown to be safe and well tolerated and no maximum tolerated dose (MTD) was reached.

"With enrollment in the Phase I portion of this trial now complete, we are evaluating next steps in this indication based on the currently evolving standard of care," said Dr. Brad Thompson, President and CEO of Oncolytics. "Our broader clinical program is increasingly focused on assessing the synergistic effects of REOLYSIN with currently approved therapies and we have completed substantial preclinical work in combination with a number of commercially available products that are relevant to this indication including radiation, Temodar and Avastin."

The clinical trial is an open-label dose escalation Phase I/II trial in which a single dose of REOLYSIN was administered by infusion to patients with recurrent malignant gliomas that are refractory to standard therapy. The administration involved the stereotactically-guided placement of a needle into the tumour, through which REOLYSIN was infused into the tumou
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
2. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
3. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
4. Oncolytics Biotech(R) Inc. Announces Unit Offering
5. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
6. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
7. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
8. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
9. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
10. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering Europe
11. Oncolytics Biotech(R) Inc. Accelerates Warrant Expiry Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015   Tocagen Inc. , a ... from Tocagen,s ongoing investigational studies were presented at ... American Association of Neurological Surgeons (AANS)/Congress of Neurological ... 2015, in Washington, D.C. ... meeting with FDA and continues to advance towards ...
(Date:5/4/2015)... ALISO VIEJO, Calif. , May 4, 2015 /PRNewswire/ ... to eliminate preventable hospitalizations, has teamed with the ... effect of Sentrian technology on 1,000 patients with chronic ... nearly 13 million Americans and is the nation,s third ... plan members of CareMore Health System , a ...
(Date:5/1/2015)...  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW Bio"), ... for solid tumor cancers, announced today that the Company ... a $40 million investment from Woodford investment funds in ... million in NW Bio on November 19, 2014.  On ... the Company for a further $40 million investment in ...
(Date:5/1/2015)... - BioAmber Inc. (NYSE: BIOA ), an industrial ... priced an underwritten registered offering of 3,900,000 shares of ... share, and granted the underwriters in the offering a ... shares of its common stock. The gross proceeds to ... to close on May 6, 2015, subject to customary ...
Breaking Biology Technology:Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 2CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 3CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 4CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 5NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3
... N.J., Feb. 6 Senesco,Technologies, Inc. ("Senesco" or ... results of preclinical animal studies focused on multiple ... the University of Waterloo.,The goal of these studies, ... test the ability of Senesco,s Factor 5A technology ...
... a unique move to provide the,unparalleled fertility and ... Bay demand and deserve, The American Fertility,Association takes ... this Sunday,Feb. 10th for the first-ever West Coast ... fertility education and advocacy nonprofit,that embeds inclusiveness in ...
... FRANCISCO, Calif., Feb. 6 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... chairman and chief executive officer, is scheduled to present,a ... 2008 in New York on,Monday, February 11 at 11:45 ... or the subsequent archived recording,log on to http://www.rigel.com ...
Cached Biology Technology:Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 2Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3The American Fertility Association Brings Fertility Education to San Francisco or Parent Hopefuls - Straight and Gay 2
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... Foundation, through its Autism Research Initiative, has signed a ... and DNA Repository (RUCDR) to establish a collection of ... collected from 2,000 families that have a single autistic ... is known, will constitute the core resource for a ...
... the dynamic world of the developing brain, neural stem cells ... These newborn neurons then migrate along the stem cell fibers ... Now, scientists have discovered a key mechanism of this migration ... other developmental processes and diseases, including cancer. The ...
... breakfast, such as whole-grain barley or rye, the regulation ... and dinner. It was previously not known that certain ... due to a combination of low GI (glycemic index) ... certain grain products. The findings are presented in a ...
Cached Biology News:Rutgers Genetics receives $7.8 million for autism research 2Rutgers Genetics receives $7.8 million for autism research 3Neural stem cell study reveals mechanism that may play role in cancer 2Neural stem cell study reveals mechanism that may play role in cancer 3Neural stem cell study reveals mechanism that may play role in cancer 4Right breakfast bread keeps blood sugar in check all day 2
... GX-1000 3-D Shaker , ,Product Information ... of the GyroTwister GX-1000 is extremely efficient, ... general mixing as well as staining gels, ... continuously adjustable across a broad range. A ...
...
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
...
Biology Products: